PALB2 and Lynch syndrome: The frequency of these mutations, especially in PALB2, which has recently been associated with a high lifetime risk of breast cancer, was similar to the frequency in high- and moderate-risk breast cancer families.7 This is a significant higher yield of potentially actionable results, compared with the 5 to 10% probability threshold endorsed by guidelines for testing for HBOC and Lynch syndrome testing.